Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISE
The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author
disclosure statements, please see the full text online (see “read the
peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2020.